- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.10. | New £4.5m initiative to address UK medicines manufacturing skills shortage | ||
| 17.10. | Vivan renews five-year lease at UK biotech hub White City Place | ||
| 16.10. | HBC Immunology shares promising results for prostate cancer co-therapy | ||
| 15.10. | Celltrion unveils promising dose escalation results for subcutaneous infliximab | ||
| 15.10. | Alleo and Ubiquigent unite to accelerate drug discovery | ||
| 14.10. | Lundbeck to acquire Longboard Pharmaceuticals in strategic deal | ||
| 14.10. | Transgene's cancer vaccine trial shows mixed results | ||
| 10.10. | Heart patient goes home hours after live-streamed valve replacement | ||
| 10.10. | Johnson & Johnson myeloma drug recommended for NHS use | ||
| 09.10. | Purespring Therapeutics secures £80 million in Series B funding | ||
| 09.10. | Sanofi launches high-dose flu vaccine in the UK | ||
| 08.10. | Kyowa Kirin announces positive interim data for lymphoma treatment | ||
| 08.10. | Astellas and AviadoBio announce exclusive gene therapy deal | ||
| 07.10. | FluoGuide submits clinical trial application for head and neck cancer treatment | ||
| 07.10. | Scottish patients first in UK to access new lung cancer treatment | ||
| 03.10. | IRLAB's new drug shows promise in treating apathy in Parkinson's patients | ||
| 03.10. | ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study | ||
| 02.10. | Insilico Medicine reports positive results for idiopathic pulmonary fibrosis therapy | ||
| 02.10. | AlzeCure's abstract on ACD856's effects to be presented at Alzheimer's conference | ||
| 01.10. | European Commission approves yuvanci for pulmonary arterial hypertension treatment | ||
| 26.09. | Sheffield A&E to implement life-saving HIV and hepatitis testing | ||
| 26.09. | Oxford drug design secures funding to combat cystic fibrosis lung infections | ||
| 24.09. | Cancer Grand Challenges launches global initiative to take on toughest problems | ||
| 24.09. | AlgoTx completes pivotal phase 2 trial for ground-breaking CIPN treatment | ||
| 19.09. | Oncologica to advance urine-based prostate cancer screening test |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
